SG11202004594SA - Anti-hbv tetrahydroisoxazolo[4,3-c]pyridine compounds - Google Patents

Anti-hbv tetrahydroisoxazolo[4,3-c]pyridine compounds

Info

Publication number
SG11202004594SA
SG11202004594SA SG11202004594SA SG11202004594SA SG11202004594SA SG 11202004594S A SG11202004594S A SG 11202004594SA SG 11202004594S A SG11202004594S A SG 11202004594SA SG 11202004594S A SG11202004594S A SG 11202004594SA SG 11202004594S A SG11202004594S A SG 11202004594SA
Authority
SG
Singapore
Prior art keywords
tetrahydroisoxazolo
hbv
pyridine compounds
pyridine
compounds
Prior art date
Application number
SG11202004594SA
Inventor
Lifang Wu
Fei Sun
Jinhua Du
Charles Z Ding
Shuhui Chen
Xiquan Zhang
Hongjiang Xu
Ling Yang
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Medshine Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd, Medshine Discovery Inc filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of SG11202004594SA publication Critical patent/SG11202004594SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
SG11202004594SA 2017-11-16 2018-11-16 Anti-hbv tetrahydroisoxazolo[4,3-c]pyridine compounds SG11202004594SA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201711138922 2017-11-16
CN201810339723 2018-04-16
PCT/CN2018/115857 WO2019096241A1 (en) 2017-11-16 2018-11-16 Anti-hbv tetrahydroisoxazolo[4,3-c]pyridine compounds

Publications (1)

Publication Number Publication Date
SG11202004594SA true SG11202004594SA (en) 2020-06-29

Family

ID=66540082

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202004594SA SG11202004594SA (en) 2017-11-16 2018-11-16 Anti-hbv tetrahydroisoxazolo[4,3-c]pyridine compounds

Country Status (7)

Country Link
US (1) US11572372B2 (en)
EP (1) EP3712139A4 (en)
JP (1) JP7250015B2 (en)
CN (1) CN111247131B (en)
PH (1) PH12020550649A1 (en)
SG (1) SG11202004594SA (en)
WO (1) WO2019096241A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021503458A (en) * 2017-11-17 2021-02-12 ノバルティス アーゲー New dihydroisoxazole compounds and their use for the treatment of hepatitis B
JP2021506852A (en) * 2017-12-21 2021-02-22 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー Isoxazole compounds for the treatment of diseases associated with HBV infection
WO2020228745A1 (en) * 2019-05-14 2020-11-19 正大天晴药业集团股份有限公司 Crystal form of tetrahydroisoxazolo[4,3-c]pyridine compound against hbv

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106166157B (en) * 2011-07-01 2019-08-02 巴鲁·S·布隆伯格研究所 As the sulfonamides heterocyclic carbamate derivatives for preventing hepatitis b virus infected antivirotic
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9550779B2 (en) * 2014-12-30 2017-01-24 Novira Therapeutics, Inc. Derivatives and methods of treating hepatitis B infections
MA41338B1 (en) * 2015-01-16 2019-07-31 Hoffmann La Roche Pyrazine compounds for the treatment of infectious diseases
JP2021503458A (en) * 2017-11-17 2021-02-12 ノバルティス アーゲー New dihydroisoxazole compounds and their use for the treatment of hepatitis B
JP2021506852A (en) 2017-12-21 2021-02-22 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー Isoxazole compounds for the treatment of diseases associated with HBV infection

Also Published As

Publication number Publication date
EP3712139A1 (en) 2020-09-23
CN111247131B (en) 2022-02-18
CN111247131A (en) 2020-06-05
US20200377517A1 (en) 2020-12-03
EP3712139A4 (en) 2021-05-05
US11572372B2 (en) 2023-02-07
JP2021503466A (en) 2021-02-12
WO2019096241A1 (en) 2019-05-23
PH12020550649A1 (en) 2021-04-26
JP7250015B2 (en) 2023-03-31

Similar Documents

Publication Publication Date Title
HK1259623A1 (en) Pyrazolo[1,5a]pyrimidine derivatives as irak4 modulators
HK1244804A1 (en) 4h-pyrrolo[3,2-c]pyridin-4-one derivatives
IL272262A (en) 1, 2 - dihydro- 3h- pyrazolo [3, 4 - d] pyrimidin -3 - one analogs
EP3154970A4 (en) Pyrrolo[2,3-c]pyridines as imaging agents for neurofibrilary tangles
ZA201700019B (en) Substituted [1,2,4]triazole compounds
EP3452481A4 (en) SUBSTITUTED IMIDAZO[1,2-b
IL260488B (en) 8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
IL280598A (en) 2,6-diamino pyridine compounds
EP3489163A4 (en) Water-degradable bag
KR20220035507A (en) [8--38-[3.2.1]-3-]1h-123--4-[8-phenylsulfonyl-38-diazabicyclo[3.2.1]oct-3-yl]1h-123-triazol-4-ylmethanones
PT3135110T (en) 1,7-diaryl-1,6-heptadien-3,5-dion derivatives, methods of making and using the same
HK1255014A1 (en) Methods for preparing substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine
SG11202004594SA (en) Anti-hbv tetrahydroisoxazolo[4,3-c]pyridine compounds
EP3338577A4 (en) Vertical waistband
EP3190111A4 (en) Pyrazolo[3,4-c]pyridine derivatives
SG11201803584RA (en) 1,4-dicarbonyl-piperidyl derivatives
HK1254800A1 (en) 2,3,4,5-tetrahydropyridin-6-amine derivatives
EP3302060A4 (en) Pyrazolo[4,3-c]quinoline derivatives for inhibition of -glucuronidase
GB201522532D0 (en) Novel pyrrolo[3,2-c]pyridine-6-amino derivatives
EP3608314A4 (en) 2,6-disubstituted pyridine derivative
ZA201907335B (en) Benzothiazole-containing silanes, method for the preparation and use thereof
HUP1700542A2 (en) Nucleosides modified by 5'-linker
AU2017904422A0 (en) Child carrying garment
AU2016904702A0 (en) Clothes hangers
IL235077A0 (en) Novel thiochromeno[2,3-c]quinolin-12-one derivatives, preparation method and application thereof